AR041218A1 - Derivados de indolilo, un proceso para su preparacion, composicion farmaceutica que lo contiene y uso del compuesto para preparar un medicamento - Google Patents

Derivados de indolilo, un proceso para su preparacion, composicion farmaceutica que lo contiene y uso del compuesto para preparar un medicamento

Info

Publication number
AR041218A1
AR041218A1 ARP030103266A ARP030103266A AR041218A1 AR 041218 A1 AR041218 A1 AR 041218A1 AR P030103266 A ARP030103266 A AR P030103266A AR P030103266 A ARP030103266 A AR P030103266A AR 041218 A1 AR041218 A1 AR 041218A1
Authority
AR
Argentina
Prior art keywords
alkyl
formula
cycloalkyl
hydrogen
bond
Prior art date
Application number
ARP030103266A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR041218A1 publication Critical patent/AR041218A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compuestos de fórmula (1), así como las sales y ésteres farmacéuticamente aceptables de los mismos. Reivindicación 1: Compuestos de fórmula (1), en donde: R1 es arilo o heteroarilo; R2 es hidrógeno, alquilo o cicloalquilo; R3 es ariloxilo,alqueniloxilo, alcoxilo o alcoxilo sustituido con de uno a tres átomos de halógeno; R4 es hidrógeno, alquilo o cicloalquilo; en donde cualquiera de R5 y R6 es una fórmula (2)y el otro es hidrógeno, alquilo o cicloalquilo y, en donde el enlace entrelos átomos de carbono Ca y Cb es un enlace carbono a carbono simple o es un doble enlace; R7 es hidrógeno, alquilo o cicloalquilo; R8 es hidrógeno, alquilo o cicloalquilo; en donde cualquiera de A y A1 es nitrógeno y el otro es oxígeno o azufre; nes 1, 2 ó 3; y las sales y ésteres farmacéuticamente aceptables de los mismos. Reivindicación 22: Un proceso para la preparación de un compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 21 comprendiendo las siguientes reacciones: a)reacción de un compuesto de acuerdo con la fórmula (3), en presencia de un compuesto de acuerdo con la fórmula (4), en donde cualquiera de R56 y R6 es una fórmula (5) y el otro es hidrógeno, alquilo o cicloalquilo y, en donde el enlace entre losátomos de carbono Ca y Cb es un enlace simple carbono carbono o un doble enlace; X es halógeno o CH3SO3; R es alquilo, arilo o aralquilo; R1 a R4, R7, R8, A, A1 y n son tal como se definen en la reivindicación 1; b) hidrogenación de un compuesto deacuerdo con la fórmula (1), en donde cualquiera de R5 y R6 es una fórmula (2) y el otro es hidrógeno, alquilo o cicloalquilo; y en donde el enlace entre los átomos de carbono Ca y Cb es un doble enlace carbono carbono; R1 a R4, R7, R8, A, A1 y n sontal como se definen en la reivindicación 1.
ARP030103266A 2002-09-12 2003-09-10 Derivados de indolilo, un proceso para su preparacion, composicion farmaceutica que lo contiene y uso del compuesto para preparar un medicamento AR041218A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02020477 2002-09-12

Publications (1)

Publication Number Publication Date
AR041218A1 true AR041218A1 (es) 2005-05-11

Family

ID=31985028

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030103266A AR041218A1 (es) 2002-09-12 2003-09-10 Derivados de indolilo, un proceso para su preparacion, composicion farmaceutica que lo contiene y uso del compuesto para preparar un medicamento

Country Status (29)

Country Link
US (1) US6890947B2 (es)
EP (1) EP1539746B1 (es)
JP (1) JP4286782B2 (es)
KR (1) KR100645684B1 (es)
CN (1) CN100577660C (es)
AR (1) AR041218A1 (es)
AT (1) ATE345340T1 (es)
AU (1) AU2003267041B2 (es)
BR (1) BR0314261A (es)
CA (1) CA2494601C (es)
DE (1) DE60309719T2 (es)
DK (1) DK1539746T3 (es)
ES (1) ES2275105T3 (es)
GT (1) GT200300194A (es)
HR (1) HRP20050212A2 (es)
MX (1) MXPA05002704A (es)
MY (1) MY135646A (es)
NO (1) NO20050667L (es)
NZ (1) NZ537979A (es)
PA (1) PA8581701A1 (es)
PE (1) PE20050050A1 (es)
PL (1) PL375878A1 (es)
PT (1) PT1539746E (es)
RU (1) RU2296759C2 (es)
SI (1) SI1539746T1 (es)
TW (1) TWI248933B (es)
UY (1) UY27975A1 (es)
WO (1) WO2004024726A1 (es)
ZA (1) ZA200501273B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10022925A1 (de) * 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
BRPI0409763A (pt) * 2003-04-17 2006-05-09 Kalypsys Inc compostos de arila como moduladores de ppars, método de modulação, método de inibição da formação de adipócitos em um mamìfero, método de tratamento de uma doença ou uma condição modulada por ppar e composição farmacêutica
US20050203151A1 (en) * 2003-12-19 2005-09-15 Kalypsys, Inc. Novel compounds, compositions and uses thereof for treatment of metabolic disorders and related conditions
US7405236B2 (en) * 2004-08-16 2008-07-29 Hoffman-La Roche Inc. Indole derivatives comprising an acetylene group
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
NO20083270L (no) * 2008-07-23 2010-01-25 Thia Medica As Indolforbindelser
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4011326A (en) 1975-07-29 1977-03-08 Merck & Co., Inc. 2-Substituted oxazolo[4,5-b]pyridine anti-inflammatory agents
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
RU2134686C1 (ru) 1992-07-03 1999-08-20 Смитклайн Бичам П.Л.С. Гетероциклическое соединение, или его таутомерная форма, и/или фармацевтически приемлемая соль, и/или фармацевтически приемлемый сольват, фармацевтическая композиция, снижающая содержание глюкозы в крови, способ лечения и/или профилактики гипергликемии
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
DE4317320A1 (de) 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
IL117208A0 (en) * 1995-02-23 1996-06-18 Nissan Chemical Ind Ltd Indole type thiazolidines
EP0820441B1 (en) * 1995-04-10 2002-06-26 Fujisawa Pharmaceutical Co., Ltd. INDOLE DERIVATIVES AS cGMP-PDE INHIBITORS
JPH09176162A (ja) * 1995-12-22 1997-07-08 Toubishi Yakuhin Kogyo Kk チアゾリジンジオン誘導体及びその製造法並びにそれを含む医薬組成物
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
AU719146B2 (en) * 1996-02-02 2000-05-04 Merck & Co., Inc. Antidiabetic agents
BR9713690B1 (pt) 1996-12-10 2009-08-11 agentes melatoninérgicos benzodioxola, benzofurano, diidrobenzofurano e benzodioxano.
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
DE19711616A1 (de) 1997-03-20 1998-09-24 Boehringer Mannheim Gmbh Verbessertes Verfahren zur Herstellung von Thiazolidindionen
US6121397A (en) 1997-07-14 2000-09-19 Xerox Corporation Polymerization processes using oligomeric compound, monomer and surfactant
HN1998000118A (es) 1997-08-27 1999-02-09 Pfizer Prod Inc 2 - aminopiridinas que contienen sustituyentes de anillos condensados.
DE69815008T2 (de) 1997-09-19 2004-04-01 Ssp Co., Ltd. Alfa-substituierte Phenylpropionsäurederivate und diese enthaltende Arzneimittel
AU1120599A (en) 1998-04-23 1999-03-08 Dr. Reddy's Research Foundation New heterocyclic compounds and their use in medicine, process for their reparation and pharmaceutical compositions containing them
GB9817118D0 (en) 1998-08-07 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
ATE263558T1 (de) 1998-08-14 2004-04-15 Hoffmann La Roche Lipasehemmer und chitosan enthaltende pharmazeutische zusammensetzungen
JP3774118B2 (ja) 1998-08-14 2006-05-10 エフ.ホフマン−ラ ロシュ アーゲー リパーゼ阻害剤を含む製薬学的組成物
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
DK1078923T3 (da) 1999-08-02 2006-07-10 Hoffmann La Roche Fremgangsmåde til fremstilling af benzothiophenderivater
DE60128475T2 (de) * 2000-07-25 2008-02-07 Merck & Co., Inc. N-substituierte indole mit anwendung in der behandlung von diabetes
SK1872003A3 (en) 2000-08-23 2003-07-01 Lilly Co Eli Oxazolyl-arylpropionic acid derivatives and their use as PPAR agonists
DE10117090B4 (de) * 2001-04-06 2013-08-14 Dr. Ing. H.C. F. Porsche Aktiengesellschaft Wassergekühlte, mehrzylindrige Brennkraftmaschine
WO2003005025A1 (en) 2001-07-03 2003-01-16 Biovitrum Ab Methods for identifying compounds modulating the activity of ppar-gamma
EP1442028A4 (en) * 2001-11-06 2009-11-04 Bristol Myers Squibb Co SUBSTITUTED ACID DERIVATIVES, WHICH APPRECIATE AS ANTIDIBILICS AND AGENTS AGAINST OBESITAS, AND METHODS
WO2003053976A1 (en) 2001-12-20 2003-07-03 Biovitrum Ab PIPAZOLO [1,5-a] PYRIMIDINE DERIVATIVES AS MODULATORS OF PPAR

Also Published As

Publication number Publication date
TWI248933B (en) 2006-02-11
DK1539746T3 (da) 2007-03-26
JP2006503029A (ja) 2006-01-26
RU2005110921A (ru) 2006-01-20
CN100577660C (zh) 2010-01-06
ES2275105T3 (es) 2007-06-01
NZ537979A (en) 2007-08-31
MY135646A (en) 2008-06-30
UY27975A1 (es) 2004-03-31
JP4286782B2 (ja) 2009-07-01
BR0314261A (pt) 2005-07-26
AU2003267041B2 (en) 2007-03-29
CN1681808A (zh) 2005-10-12
PE20050050A1 (es) 2005-02-18
MXPA05002704A (es) 2005-05-05
PT1539746E (pt) 2007-02-28
RU2296759C2 (ru) 2007-04-10
SI1539746T1 (sl) 2007-04-30
CA2494601C (en) 2009-09-29
EP1539746B1 (en) 2006-11-15
PL375878A1 (en) 2005-12-12
KR20050042809A (ko) 2005-05-10
TW200418845A (en) 2004-10-01
CA2494601A1 (en) 2004-03-25
NO20050667L (no) 2005-06-08
PA8581701A1 (es) 2004-04-23
GT200300194A (es) 2004-04-15
HRP20050212A2 (en) 2006-05-31
DE60309719D1 (de) 2006-12-28
US20040053979A1 (en) 2004-03-18
WO2004024726A1 (en) 2004-03-25
EP1539746A1 (en) 2005-06-15
KR100645684B1 (ko) 2006-11-15
US6890947B2 (en) 2005-05-10
DE60309719T2 (de) 2007-09-20
ATE345340T1 (de) 2006-12-15
ZA200501273B (en) 2006-08-30
AU2003267041A1 (en) 2004-04-30

Similar Documents

Publication Publication Date Title
AR041218A1 (es) Derivados de indolilo, un proceso para su preparacion, composicion farmaceutica que lo contiene y uso del compuesto para preparar un medicamento
ES2220529T3 (es) Dibenzopiranos utiles como antagonistas del receptor de los glucocorticoides, en el tratamiento de la diabetes.
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
AR044796A1 (es) Derivados de pirido (2, 1-a) isoquinolina como inhibidores de la dpp iv
CU23413B7 (es) Nuevos derivados de benzoimidazol útiles como agentes antiproliferativos
ECSP099638A (es) Nuevo compuesto de adenina
AR059314A1 (es) Derivados de las benzamidas y heteroarenos
CO5540385A2 (es) Derivados quirales de acido oxazol arilpropionico, su metodo de sintesis ycomposiciones farmaceuticas que los contienen
AR044795A1 (es) Derivados de pirido [2,1-a] isoquinolina como inhibidores de la dpp-iv
AR035892A1 (es) Derivados de oxazol, proceso para su preparacion, composiciones farmaceuticas que los comprenden, y el uso de dichos compuestos en la preparacion de medicamentos
AR065344A1 (es) Derivados de azonia biciclo octano como activadores del receptor m3
SV2003000876A (es) Quinazolinas como inhibidores de mmp-13
CO5650253A2 (es) Piperazina con grupo fenilo or-sustituido y su uso como inhibidores de glyt1
CO5580815A2 (es) Derivados de adamantana, procesos para su preparacion y composiciones farmaceuticas que los contienen
PE20021004A1 (es) Derivados de piperidina como inhibidores de la ccr5
AR020165A1 (es) Derivados de pirimidinas sustituidas, su procedimiento de preparacion, composiciones farmaceuticas que las contienen y el uso de los mismos para la preparacion de medicamentos
AR039927A1 (es) Derivados de isoindolona, proceso de preparacion y compuestos intermedios de este proceso, su uso como medicamentos, y composiciones farmaceuticas que los contienen
PE20080342A1 (es) Inhibidores de proteasa de hiv de 2-(amino-sustituido)-benzotiazol sulfonamida
AR041883A1 (es) Compuestos de piridopirimidinona, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
AR041882A1 (es) Compuestos de imidazopiridina, un procedimiento para su preparacion y composiciones farmaceuticas que los contienen
AR043563A1 (es) Inhibidores de catepsina s
BRPI0113837B8 (pt) compostos mutilinas com atividade antimicrobiana e composição farmacêutica que os compreende
AR057651A1 (es) Derivados n-amida de 8-azabiciclo[3.2.1]oct-3-ilo como antagonistas de ccr1, una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas
AR027578A1 (es) Derivados de indano

Legal Events

Date Code Title Description
FB Suspension of granting procedure